SCHEMBL1336965

SCHEMBL1336965

CCn1ccc(-c2ccc3c(c2)c2cc(-c4ccc(Cl)cc4Cl)c(=O)n(C)c2n3C(F)F)n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 2/20 0.33
▸ GABRA1 P14867 5/20 0.32
▸ GABRG2 P18507 4/20 0.32
▸ GABRB3 P28472 4/20 0.32
▸ GABRA5 P31644 4/20 0.32
▸ F2RL3 Q96RI0 1/20 0.32
▸ CNR1 P21554 8/20 0.32
▸ CNR2 P34972 8/20 0.32
▸ MARS1 P56192 1/20 0.32
▸ EGFR P00533 1/20 0.31
▸ ALOX5 P09917 1/20 0.31
▸ ADORA3 P0DMS8 1/20 0.31
▸ ADRA2C P18825 1/20 0.31
▸ MAPK3 P27361 1/20 0.31
▸ OPRL1 P41146 1/20 0.31
▸ SLC6A3 Q01959 1/20 0.31
▸ SLC18A2 Q05940 1/20 0.31
▸ MAPK14 Q16539 1/20 0.31
▸ TMEM97 Q5BJF2 1/20 0.31
▸ SIGMAR1 Q99720 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339409 0.89 HSD11B1 (0.36) HSD11B1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1338638 0.82 GABRA1 (0.34) GABRA1GABRG2GABRB3GABRA5
SCHEMBL1339158 0.82 MARS1 (0.36) HSD11B1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1338134 0.82 CNR1 (0.33) HSD11B1GABRA1F2RL3CNR1CNR2
SCHEMBL1337038 0.81 MARS1 (0.39) GABRA1CNR1CNR2MARS1EGFR
SCHEMBL1338637 0.80 GABRA1 (0.38) HSD11B1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1336826 0.80 CNR1 (0.35) HSD11B1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1336885 0.79 CNR1 (0.37) CNR1CNR2EGFRKDM4EALDH1A1
SCHEMBL1337210 0.79 KDM4E (0.37) HSD11B1GABRA1GABRG2GABRB3GABRA5
SCHEMBL1338200 0.78 GABRA1 (0.36) HSD11B1GABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 HSD11B1 107/4885GABRA1 1457/4885GABRG2 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback